Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 41


Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins.

Tussey L, Strout C, Davis M, Johnson C, Lucksinger G, Umlauf S, Song L, Liu G, Abraham K, White CJ.

Open Forum Infect Dis. 2016 Jan 29;3(1):ofw015. doi: 10.1093/ofid/ofw015. eCollection 2016 Jan.


A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators.

N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29.


Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.

Hopkins RJ, Howard C, Hunter-Stitt E, Kaptur PE, Pleune B, Muse D, Sheldon E, Davis M, Strout C, Vert-Wong K.

Vaccine. 2014 Apr 17;32(19):2217-24. doi: 10.1016/j.vaccine.2014.01.073. Epub 2014 Mar 6.


Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5.


Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.

Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.

Vaccine. 2014 May 1;32(21):2507-17. doi: 10.1016/j.vaccine.2013.09.074. Epub 2013 Oct 11.


Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.

Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; NN8022-1923 Investigators.

Int J Obes (Lond). 2013 Nov;37(11):1443-51. doi: 10.1038/ijo.2013.120. Epub 2013 Jul 1. Erratum in: Int J Obes (Lond). 2013 Nov;37(11):1514. Int J Obes (Lond). 2015 Jan;39(1):187.


Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.

Vaccine. 2013 May 1;31(19):2358-65. doi: 10.1016/j.vaccine.2013.03.008. Epub 2013 Mar 13.


Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.

Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF.

Lancet Infect Dis. 2013 Mar;13(3):238-50. doi: 10.1016/S1473-3099(12)70345-6. Epub 2013 Jan 29.


Treatment with a novel topical nanoemulsion (NB-001) speeds time to healing of recurrent cold sores.

Kircik L, Jones TM, Jarratt M, Flack MR, Ijzerman M, Ciotti S, Sutcliffe J, Boivin G, Stanberry LR, Baker JR; NB-001 Study Group.

J Drugs Dermatol. 2012 Aug;11(8):970-7.


Detection of Bacillus anthracis from spores and cells by loop-mediated isothermal amplification without sample preparation.

Dugan L, Bearinger J, Hinckley A, Strout C, Souza B.

J Microbiol Methods. 2012 Sep;90(3):280-4. doi: 10.1016/j.mimet.2012.05.022. Epub 2012 Jun 5.


A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM; BLOSSOM Clinical Trial Group.

J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77. doi: 10.1210/jc.2011-1256. Epub 2011 Jul 27.


Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.


Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A.

Vaccine. 2011 Jul 12;29(31):4897-902. doi: 10.1016/j.vaccine.2011.05.001. Epub 2011 May 17.


Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.


Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

Chrysant SG, Neutel JM, Ferdinand KC; INCLUSIVE investigators.

J Natl Med Assoc. 2009 Apr;101(4):300-7.


Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.


Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators.

Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.


Studies of thioguanine-resistant lymphocytes induced by in vivo irradiation of mice.

Jones IM, Burkhart-Schultz K, Strout CL, Nelson DO.

Environ Mol Mutagen. 2008 Jun;49(5):343-50. doi: 10.1002/em.20388.


Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM; MK-0974 Protocol 004 study group.

Neurology. 2008 Apr 15;70(16):1304-12. Epub 2007 Oct 3.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk